Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

Tiberi, Simon; Sotgiu, Giovanni; D’Ambrosio, Lia; Centis, Rosella; Arbex, Marcos Abdo; Arrascue, Edith Alarcon; Alffenaar, Jan Willem; Caminero, José A.; Gaga, Mina; Gualano, Gina; Skrahina, Alena; Solovič, Ivan; Sulis, Giorgia; Tadolini, Marina; Guizado, Valentina Alarcon; Lorenzo, Saverio De; Arias, Aurora Jazmín Roby; Scardigli, Anna; Akkerman, Onno W.; Aleksa, Alena; Artsukevich, Janina; Avchinko, Vera; Bonini, Eduardo Henrique; Marin, Felix Antonio Chong; López, Lorena Collahuazo; Vries, Gerard de; Dore, S. E.; Kunst, Heinke; Matteelli, Alberto; Moschos, Charalampos; Palmieri, Fabrizio; Papavasileiou, Apostolos; Payen, Marie Christine; Piana, Andrea; Spanevello, Antonio; Vasquez, Dante Vargas; Viggiani, Pietro; White, Verónica; Zumla, Alimuddin; Migliori, Giovanni Battista

doi:10.1093/cid/ciw088

Cited by 34 publications

(35 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this regard, as of today, some repurposed drugs can be used including, among others, linezolid [29,30,31,32,33,34,35] and the carbapenems [36,37,38,39,40,41]. …”

Section: Introductionmentioning

confidence: 99%

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

Migliori

Pontali

Sotgiu

et al. 2017

IJMS

Self Cite

View full text Add to dashboard Cite

The new drugs delamanid and bedaquiline are increasingly being used to treat multidrug-resistant (MDR-) and extensively drug-resistant tuberculosis (XDR-TB). The World Health Organization, based on lack of evidence, recommends their use under specific conditions and not in combination. No systematic review has yet evaluated the efficacy, safety, and tolerability of delamanid and bedaquiline used in combination. A search of peer-reviewed, scientific evidence was carried out, aimed at evaluating the efficacy/effectiveness, safety, and tolerability of delamanid and bedaquiline-containing regimens in individuals with pulmonary/extrapulmonary disease, which were bacteriologically confirmed as M/XDR-TB. We used PubMed to identify any relevant manuscripts in English up to the 23 December 2016, excluding editorials and reviews. Three out of 75 manuscripts retrieved satisfied the inclusion criteria, whilst 72 were excluded for dealing with only one drug (three studies), being recommendations (one study) or identifying need for their use (one study), focusing on drug resistance aspects (six studies) or being generic reviews/other studies (61 papers). The studies retrieved reported two XDR-TB cases observed for six months and achieving consistent sputum smear and culture conversion. Case 2 experienced a short break of bedaquiline, which was re-started after introducing verapamil. After a transient and symptom-free increase of the QT interval from week 5 to 17, it then decreased below the 500 ms threshold.

show abstract

“…In this regard, as of today, some repurposed drugs can be used including, among others, linezolid [29,30,31,32,33,34,35] and the carbapenems [36,37,38,39,40,41]. …”

Section: Introductionmentioning

confidence: 99%

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

Migliori

Pontali

Sotgiu

et al. 2017

IJMS

Self Cite

View full text Add to dashboard Cite

show abstract

“…Imipenem/cilastatin and meropenem, combined with clavulanic acid, seem to have a promising activity, while being well tolerated (34)(35)(36)(37). In the direct comparison meropenem performs better than imipenem (37).…”

Section: Which Drugs Might Be Upgradedmentioning

confidence: 99%

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives

Rendón¹,

Tiberi

Scardigli

et al. 2016

J. Thorac. Dis.

Self Cite

View full text Add to dashboard Cite

“…Although it is now a candidate to be a companion drug, there is increasing evidence that it may play a future core drug role [19,40], especially because of its possible good bactericidal activity. Based on the existing evidence, the best carbapenem would probably be meropenem [41,42], although imipenem/cilastatin (often more easily available) [42,43] or ertapenem (given the possibility to administer it once a day intramuscularly, it can act as switch therapy useful for ambulatory/home care) might also have a role [44][45][46]. However, given the need for parenteral administration with carbapenems, delamanid is also a potential choice (needing electrocardiogram monitoring), as discussed previously.…”

Section: Regimen Composition and Possible Alternativesmentioning

confidence: 99%

Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases

et al. 2017

Self Cite

View full text Add to dashboard Cite

Effectiveness and Safety of Imipenem-Clavulanate Added to an Optimized Background Regimen (OBR) Versus OBR Control Regimens in the Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

Abstract: Figure 1. Time to sputum culture conversion in patients with multidrug-resistant tuberculosis exposed or not exposed to imipenem-clavulanate (P = .77).

Cited by 34 publications

References 12 publications

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives

Proposal for a standardised treatment regimen to manage pre- and extensively drug-resistant tuberculosis cases

Contact Info

Product

Resources

About